Clinical trials: No Reflow Phenomenon, open to volunteers
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
Acute Cerebrovascular Accident, Thrombectomy
Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy
Introduction: Endovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion.
- Conditions
- Acute Cerebrovascular Accident, Thrombectomy, Cerebral Revascularization, No Reflow Phenomenon
- Trial name
- RESTORE-AIS (NCT07534319)
- Testing
- No planned intervention
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
No-Reflow Phenomenon, Coronary Artery Disease
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden…
- Conditions
- No-Reflow Phenomenon, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- NCT05427786
- Testing
- Nicorandil
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Korea University Anam Hospital
ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
- Conditions
- ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
- Trial name
- AMPACT (NCT07536802)
- Testing
- Adenosine pre-medication, Standard care
- Where
- 2 sites in Pakistan
- Volunteers
- 1,148 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
STEMI, No-Reflow Phenomenon
Insulin Resistance and Its Association With no Reflow Phenomenon After Primary PCI in Type II Diabetic STEMI Patients.
To investigate the relationship between the TyG index, coronary lesion complexity assessed by the SYNTAX score, and the development of the no-reflow phenomenon in STEMI patients with T2DM.
- Conditions
- STEMI, No-Reflow Phenomenon, Diabetic Patient
- Trial name
- NCT07706335
- Testing
- PCI
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
ST Segment Elevation Myocardial Infarction (STEMI), No Reflow Phenomenon
The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow
The aim of this work is to study the role of intracoronary adrenaline administration as a preventive tool for no reflow in patients undergoing primary PCI.
- Trial name
- NCT06847568
- Testing
- Adrenaline
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Ain Shams University
STEMI, Large Thrombus Burden
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality.
- Conditions
- STEMI, Large Thrombus Burden, No-Reflow Phenomenon
- Trial name
- UPFRONT-STEMI (NCT05393557)
- Testing
- Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury
- Volunteers
- 626 people
- Sponsor
- Cairo University
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine